Literature DB >> 1479599

A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling.

D G Evans1, S M Huson, D Donnai, W Neary, V Blair, V Newton, T Strachan, R Harris.   

Abstract

The major defining features, age at onset of symptoms, and survival in 150 patients with type 2 neurofibromatosis (NF2) have been studied. The mean age at onset was 21.57 years (n = 110) and no cases presented after 55 years of age. Patients presented with symptoms attributable to vestibular schwannomas (acoustic neuroma), cranial meningiomas, and spinal tumours. In 97 cases studied personally by the authors, skin and eye examination were found to be useful to detect early signs of the condition. Examination of the skin is likely to assist in early diagnosis in at least 10% of cases and examination of the eye for a lens opacity or cataract in at least as many again. There are marked interfamilial differences in disease severity and tumour susceptibility. Vestibular schwannomas are not fully penetrant, but the condition is usually expressed in another way. Alteration to the current diagnostic criteria is advocated to cover the lack of provision for new mutations. A screening protocol is proposed and the effect of disease heterogeneity on management is discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1479599      PMCID: PMC1016199          DOI: 10.1136/jmg.29.12.847

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  18 in total

1.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

2.  Bilateral cerebellopontine angle tumors in neurofibromatosis type 2.

Authors:  D Baldwin; T T King; E Chevretton; A W Morrison
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

3.  Eye findings in bilateral acoustic (central) neurofibromatosis: association with presenile lens opacities and cataracts but absence of Lisch nodules.

Authors:  M A Pearson-Webb; M I Kaiser-Kupfer; R Eldridge
Journal:  N Engl J Med       Date:  1986-12-11       Impact factor: 91.245

4.  Acoustic neuroma in the last months of pregnancy.

Authors:  J Allen; R Eldridge; T Koerber
Journal:  Am J Obstet Gynecol       Date:  1974-06-15       Impact factor: 8.661

5.  Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene.

Authors:  B R Seizinger; G A Rouleau; L J Ozelius; A H Lane; A G Faryniarz; M V Chao; S Huson; B R Korf; D M Parry; M A Pericak-Vance
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

6.  Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17.

Authors:  D Barker; E Wright; K Nguyen; L Cannon; P Fain; D Goldgar; D T Bishop; J Carey; B Baty; J Kivlin
Journal:  Science       Date:  1987-05-29       Impact factor: 47.728

7.  Neurofibromatosis type 1 with bilateral acoustic neuromas.

Authors:  V V Michels; J P Whisnant; J A Garrity; G M Miller
Journal:  Neurofibromatosis       Date:  1989

8.  Bilateral retinal hamartomas in neurofibromatosis type 2.

Authors:  W V Good; M C Erodsky; M S Edwards; W F Hoyt
Journal:  Br J Ophthalmol       Date:  1991-03       Impact factor: 4.638

9.  Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment.

Authors:  R L Martuza; R G Ojemann
Journal:  Neurosurgery       Date:  1982-01       Impact factor: 4.654

10.  Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis.

Authors:  W R Kanter; R Eldridge; R Fabricant; J C Allen; T Koerber
Journal:  Neurology       Date:  1980-08       Impact factor: 9.910

View more
  35 in total

Review 1.  Paternal factors and schizophrenia risk: de novo mutations and imprinting.

Authors:  D Malaspina
Journal:  Schizophr Bull       Date:  2001       Impact factor: 9.306

Review 2.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

3.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

4.  Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.

Authors:  Camille Louvrier; Eric Pasmant; Audrey Briand-Suleau; Joëlle Cohen; Patrick Nitschké; Juliette Nectoux; Lucie Orhant; Cécile Zordan; Cyril Goizet; Stéphane Goutagny; Dominique Lallemand; Michel Vidaud; Dominique Vidaud; Michel Kalamarides; Béatrice Parfait
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

5.  Spinal ependymomas in NF2: a surgical disease?

Authors:  M Kalamarides; W Essayed; J P Lejeune; R Aboukais; O Sterkers; D Bernardeschi; M Peyre; S K Lloyd; S Freeman; C Hammerbeck-Ward; M Kellett; S A Rutherford; D G Evans; O Pathmanaban; A T King
Journal:  J Neurooncol       Date:  2017-11-29       Impact factor: 4.130

6.  Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.

Authors:  C L Wu; N Thakker; W Neary; G Black; R Lye; R T Ramsden; A P Read; D G Evans
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

7.  The genetic testing of children.

Authors:  A Fryer
Journal:  J R Soc Med       Date:  1997-08       Impact factor: 5.344

Review 8.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

9.  Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Authors:  Michel Kalamarides; Michiko Niwa-Kawakita; Hélène Leblois; Vincent Abramowski; Michel Perricaudet; Anne Janin; Gilles Thomas; David H Gutmann; Marco Giovannini
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.